Press Releases Kadimastem Ltd

Equities

KDST

IL0011284614

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 06:19:49 12/05/2024 pm IST			5-day change	1st Jan Change
488.9 ^ILa	+2.07%		-3.85%	-17.55%

28/03	Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
28/02	IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC	28/02	AQ
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company	28/02	AQ
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq	16/02	AQ
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India	07/02	AQ
A peer reviewed article on Kadimastem's AstroRxÃ‚® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology	25/01	AQ
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA	22/01	AQ
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes	07/11	AQ
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes	20/23/20	AQ
Kadimastem : Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS	09/21/09	PR
Kadimastem : Announces Executive Management Changes	01/21/01	PR
Kadimastem : AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial	16/20/16	AQ
Kadimastem : Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS	03/20/03	PR
Kadimastem : Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS	06/20/06	PR
Kadimastem : Announces the Completion of Treatment for Cohort B of Its Phase 1/2a Clinical Trial in ALS Patients	23/19/23	PR
Kadimastem : Intends to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol Following Recent Positive Interim Results	18/19/18	PR
Kadimastem : to Present Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv, Israel	11/19/11	PR
Kadimastem : Announces Promising Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS	24/19/24	PR
Kadimastem : Announces Leadership Changes	29/19/29	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW